Stocktoria
Artiva Biotherapeutics, Inc. ARTV
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-07-19
Chart by TradingView
1/9
Piotroski F — financial health
-2.34
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Revenue | $0 | $251,000 | $33.5M |
| Operating income | -$89.8M | -$67.3M | -$30.7M |
| Net income | -$83.9M | -$65.4M | -$28.7M |
| Operating cash flow | -$76.8M | -$55.0M | -$47.4M |
| Free cash flow | -$79.3M | -$55.7M | -$50.7M |
| Total assets | $130.9M | $209.6M | $105.1M |
| Total liabilities | $21.0M | $22.9M | $50.7M |
| Shareholders' equity | $110.0M | $186.6M | -$162.0M |
| Ratios | |||
| Operating margin | — | -26805.6% | -91.6% |
| Net margin | — | -26045.0% | -85.8% |
| FCF margin | — | -22180.9% | -151.3% |
| Return on assets | -64.0% | -31.2% | -27.3% |
| Return on equity | -76.3% | -35.0% | 17.7% |
| Current ratio | 8.61 | 15.39 | 6.53 |
| Revenue growth | -100.0% | -99.3% | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 80,038 | $515,445 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -2.34 (distress)
- Working capital / assets 0.76
- Retained earnings / assets -2.524
- EBIT / assets -0.686
- Equity / liabilities 5.244
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001817241 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.